

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAVXR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|----|--------|---|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | JAN 02 | STN pricing information for 2008 now available |
| NEWS | 3 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS | 4 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS | 5 | JAN 28 | MARPAT searching enhanced |
| NEWS | 6 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS | 7 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |
| NEWS | 8 | JAN 28 | MEDLINE and LMEDLINE reloaded with enhancements |
| NEWS | 9 | FEB 08 | STN Express, Version 8.3, now available |
| NEWS | 10 | FEB 20 | PCI now available as a replacement to DPCI |
| NEWS | 11 | FEB 25 | IFIREF reloaded with enhancements |
| NEWS | 12 | FEB 25 | IMSPRODUCT reloaded with enhancements |
| NEWS | 13 | FEB 29 | WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification |
| NEWS | 14 | MAR 31 | IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats |
| NEWS | 15 | MAR 31 | CAS REGISTRY enhanced with additional experimental spectra |
| NEWS | 16 | MAR 31 | CA/CAPLUS and CASREACT patent number format for U.S. applications updated |
| NEWS | 17 | MAR 31 | LPCI now available as a replacement to LDPCI |
| NEWS | 18 | MAR 31 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS | 19 | APR 04 | STN AnaVist, Version 1, to be discontinued |
| NEWS | 20 | APR 15 | WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats |
| NEWS | 21 | APR 28 | EMBASE Controlled Term thesaurus enhanced |
| NEWS | 22 | APR 28 | IMSRESEARCH reloaded with enhancements |
| NEWS | 23 | MAY 30 | INPAFAMDB now available on STN for patent family searching |
| NEWS | 24 | MAY 30 | DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option |
| NEWS | 25 | JUN 06 | EPFULL enhanced with 260,000 English abstracts |
| NEWS | 26 | JUN 06 | KOREAPAT updated with 41,000 documents |
| NEWS | 27 | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications |

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:27:38 ON 17 JUN 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 17:28:17 ON 17 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUN 2008 HIGHEST RN 1028528-04-2

DICTIONARY FILE UPDATES: 16 JUN 2008 HIGHEST RN 1028528-04-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\pyrazol.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24

chain bonds :

7-11 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 12-22
13-14 13-24 14-15 16-17 16-21 17-18 18-19 19-20 20-21 22-23 23-24

exact/norm bonds :

11-12 11-15 12-13 12-22 13-14 13-24 14-15 22-23 23-24

exact bonds :

7-11 15-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19
19-20 20-21

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 17:29:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 243 TO 877


PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=> D L1

L1 HAS NO ANSWERS


L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> D L2

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 737791-24-1 REGISTRY
ED Entered STN: 02 Sep 2004
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)
MF C23 H22 N4 O
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d L2 ide\
'IDE\' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number

CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.


The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):ide

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 737791-24-1 REGISTRY
ED Entered STN: 02 Sep 2004
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)
MF C23 H22 N4 O
SR CA
LC STN Files: CA, CAPLUS, CASREACT




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2 ide

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 737791-24-1 REGISTRY


ED Entered STN: 02 Sep 2004
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)
 MF C23 H22 N4 O
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d l1 1-22 ide
 L1 HAS NO ANSWERS
 'IDE ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
 Structure Formats
 SIA ----- Structure Image, Attributes, and map table if it contains
 data. (Default)
 SIM ----- Structure IMage.
 SAT ----- Structure ATtributes and map table if it contains data.
 SCT ----- Structure Connection Table and map table if it contains
 data.
 SDA ----- All Structure Data (image, attributes, connection table and
 map table if it contains data).
 NOS ----- NO Structure data.
 ENTER STRUCTURE FORMAT (SIM), NOS:sim
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 12 2

L2 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 737791-22-9 REGISTRY
ED Entered STN: 02 Sep 2004
CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)
MF C20 H15 Cl N4
SR CA
LC STN Files: CA, CAPLUS, CASREACT




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 12 22

L2 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 476474-60-9 REGISTRY
ED Entered STN: 17 Dec 2002
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)
OTHER NAMES:
CN 8-Fluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
MF C21 H17 F N4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 12 5

L2 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 700874-60-8 REGISTRY
ED Entered STN: 29 Jun 2004
CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H27 N5 O5
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


=> S FULL L1
FULL SEARCH INITIATED 17:36:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 799 TO ITERATE

100.0% PROCESSED 799 ITERATIONS 569 ANSWERS
SEARCH TIME: 00.00.01

L3 569 SEA SSS FUL L1

=> d L3 500

L3 ANSWER 500 OF 569 REGISTRY COPYRIGHT 2008 ACS on STN
RN 476475-38-4 REGISTRY
ED Entered STN: 17 Dec 2002
CN Quinoline, 6-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)
OTHER NAMES:
CN 6-Benzo[1,3]dioxol-5-yl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
MF C28 H22 N4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> S L1 SSS FULL
FULL SEARCH INITIATED 17:41:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 799 TO ITERATE

100.0% PROCESSED 799 ITERATIONS 569 ANSWERS
SEARCH TIME: 00.00.01

L4 569 SEA SSS FUL L1

=> enter CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 380.38 380.59

FILE 'CAPLUS' ENTERED AT 17:42:12 ON 17 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 16 Jun 2008 (20080616/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> S L4
L5 9 L4

=> d scan

L5 9 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM C07D487-04
ICS A61K031-4709; A61P009-04
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
modulators
ST mixed lineage kinase modulator pyrrolopyrazole quinoline prepn
IT Heart, disease
(failure; preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed
lineage kinase modulators)
IT Cardiovascular agents
Human
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
modulators)
IT 391680-74-3, Protein kinase MLK7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
modulators)
IT 700872-48-6P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic Acid trifluoroacetate
700872-67-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700874-15-3P,
[2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
yl]quinolin-7-yl]benzoylamino]ethyl]carbamic acid tert-butyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
modulators)
IT 700871-90-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
yl]-7-thiophen-2-ylquinoline trifluoroacetate 700871-92-7P,
7-(4-Methylthiophene-2-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinoline Trifluoroacetate 700871-94-9P
700871-96-1P, 7-Phenyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700871-98-3P
700872-00-0P 700872-02-2P 700872-04-4P
700872-06-6P 700872-08-8P 700872-10-2P,
7-(3-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinoline trifluoroacetate 700872-12-4P,
7-(4-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinoline trifluoroacetate 700872-14-6P,
7-(3-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
3-yl]quinoline trifluoroacetate 700872-16-8P,
7-(4-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
3-yl]quinoline trifluoroacetate 700872-18-0P
700872-20-4P, N-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanesulfonamide trifluoroacetate
700872-22-6P, 7-(2-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-24-8P, 7-(3-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-26-0P, 7-(4-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-28-2P, 7-(4-Methoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-30-6P, 7-(4-Fluoro-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,5-
dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate

700872-32-8P, 7-(4-Fluoro-2-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-34-0P, 7-(4-Bromophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-36-2P
 , 7-(4-Ethylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-38-4P,
 7-(4-Methylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-40-8P,
 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzonitrile trifluoroacetate 700872-42-0P
 700872-44-2P, 1-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]ethanone trifluoroacetate
 700872-46-4P, 2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]benzamide trifluoroacetate
 700872-50-0P, 7-(3,5-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-52-2P, 7-(4-Methoxy-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-54-4P 700872-56-6P 700872-58-8P
 700872-60-2P, 7-(2-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-62-4P
 700872-64-6P, 7-(4-(Methanesulfinyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-66-8P, 7-Benzo[1,3]dioxol-5-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-68-0P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic Acid trifluoroacetate
 700872-70-4P, 7-(3,5-Bis-trifluoromethylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-72-6P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
 700872-74-8P, 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
 700872-76-0P, 7-(4-Isobutylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-78-2P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenoxy]acetic Acid trifluoroacetate
 700872-80-6P, 7-Benzo[b]thiophene-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-82-8P, 7-Benzofuran-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-84-0P
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-3-yl]quinoline trifluoroacetate 700872-86-2P,
 7-Furan-3-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-88-4P, 7-(4-Methyl-3-nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-90-8P, 7-(4-Cyclohexylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate 700872-92-0P,
 7-[4-(Benzo[b]thiophene-3-yl)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-93-1P
 , 7-(3,4-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-94-2P, 4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700872-95-3P, 3-[4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid 700872-96-4P, 7-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-97-5P,
 7-(4-Methoxyphenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-99-7P, 7-Phenyl-4-[2-(6-

methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 trifluoroacetate 700873-01-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-2-yl]quinoline
 trifluoroacetate 700873-02-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)quinoline
 700873-03-6P, 7-(4-Chlorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-05-8P,
 7-Furan-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline trifluoroacetate 700873-07-0P 700873-09-2P
 700873-11-6P 700873-13-8P 700873-15-0P
 700873-17-2P 700873-19-4P, 7-Cyclohexyl-4-[2-(pyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700873-22-9P 700873-24-1P, [4-[4-[2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]acetic acid
 trifluoroacetate 700873-26-3P, 7-(4-(Methanesulfonyl)phenyl)-4-
 [2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 trifluoroacetate 700873-28-5P 700873-30-9P
 700873-32-1P 700873-34-3P, 5-[4-[2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]isophthalic acid
 trifluoroacetate 700873-36-5P 700873-38-7P,
 7-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophene-5-yl)-4-[2-(pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700873-40-1P 700873-42-3P 700873-45-6P,
 7-(6-Methoxypyridazin-3-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinoline difluoroacetate 700873-47-8P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
 [pyrimidin-2-yl]quinoline difluoroacetate 700873-49-0P,
 4-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-7-yl]phenyl]butyramide trifluoroacetate 700873-51-4P
 700873-53-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]-7-[pyrimidin-5-yl]quinoline difluoroacetate
 700873-55-8P 700873-57-0P 700873-59-2P,
 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-
 7-yl]thiophene-2-sulfonic acid amide trifluoroacetate 700873-61-6P
 700873-63-8P 700873-64-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide
 700873-65-0P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-66-1P,
 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-
 7-yl]benzenesulfonamide 700873-68-3P 700873-71-8P
 700873-73-0P, 7-Pyrazol-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-75-2P
 700873-76-3P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]piperazine-1-carboxylic acid tert-butyl ester
 700873-78-5P, 7-Piperidin-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-80-9P
 700873-81-0P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid methyl ester
 700873-83-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionamide 700873-85-4P
 700873-88-7P 700873-91-2P 700873-93-4P
 700873-96-7P 700873-98-9P 700874-01-7P
 700874-04-0P 700874-07-3P 700874-09-5P,
 7-[4-(2-Methoxyethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-11-9P
 , 7-[4-(2-Fluoroethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-14-2P
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-
 (2,2,2-trifluoroethoxy)phenyl]quinoline trifluoroacetate
 700874-17-5P, Piperidin-1-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-

pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
 700874-18-6P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]thiomorpholin-4-ylmethanone
 700874-20-0P, Morpholin-4-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
 700874-22-2P, N-Carbamoylmethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-23-3P
 , N-[2-(Isopropylamino)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-24-4P,
 N-[2-(tert-Butylsulfanyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-26-6P,
 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic Acid Ethyl Ester
 700874-28-8P, N-(1,1-Dioxotetrahydrothiophene-3-yl)-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-30-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]piperidine-1-carboxylic acid tert-butyl ester 700874-32-4P
 700874-34-6P, N-(2-(Morpholin-4-yl)ethyl)-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide
 700874-36-8P, (1,1-Dioxothiophene-3-yl)[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
 700874-38-0P 700874-40-4P 700874-42-6P,
 N,N-Dimethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-44-8P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic acid tert-butyl ester 700874-46-0P,
 N-Methyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-48-2P, N-[2-(Methanesulfonyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-50-6P,
 N-[(Dimethylamino)methylene]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-52-8P,
 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-55-1P 700874-57-3P
 700874-59-5P 700874-61-9P 700874-69-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)

IT 78-94-4, Methyl vinyl ketone, reactions 591-19-5, 3-Bromoaniline
 701-34-8, 4-Bromobenzenesulfonamide 934-60-1, 6-Methylpyridine-2-carboxylic Acid 1765-93-1, 4-Fluorophenylboronic acid 4584-46-7,
 2-Dimethylaminoethyl chloride hydrochloride 4635-59-0, 4-Chlorobutyryl chloride 5350-57-2, Benzophenone hydrazone 6165-68-0,
 Thiophene-2-boronic acid 6226-25-1 7565-57-3, Cyclohexylzinc bromide 26510-52-1 34743-88-9, 2-(4-Bromophenoxy)ethanol 57260-71-6
 57260-73-8, (2-Aminoethyl)carbamic acid tert-butyl ester 73183-34-3
 82121-06-0, 7-Bromoquinolin-4-ol 118486-94-5, Tri-(n-butyl)(furan-2-yl)stannane 135884-31-0, 1-(tert-Butoxycarbonyl)pyrrole-2-boronic acid 138900-55-7, 1-(Triisopropylsilyl)pyrrole-3-boronic acid 150401-96-0
 151169-75-4, 3,4-Dichlorophenylboronic acid 214360-60-8,
 N-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]acetamide
 700872-01-1, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenol

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)

IT 13602-11-4P, 6-Methylpyridine-2-carboxylic Acid Methyl Ester

20386-22-5P, 1-Aminopyrrolidin-2-one hydrochloride 79289-25-1P
 79289-48-8P, 1-(Benzhydrylideneamino)pyrrolidin-2-one 141052-31-5P,
 7-Bromo-4-methylquinoline 476472-31-8P, 2-(7-Bromoquinolin-4-yl)-1-(6-
 methylpyridin-2-yl)ethanone 476472-35-2P, 2-(7-Bromoquinolin-4-yl)-1-
 pyridin-2-ylethanone 476473-60-6P, 1-[2-(7-Bromoquinolin-4-yl)-1-(6-
 methylpyridin-2-yl)ethylideneamino]pyrrolidin-2-one 476473-64-0P,
 1-[[2-(7-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-
 one 476473-88-8P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazole-3-carboxylic acid ethyl ester 476473-89-9P,
 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-
 carboxylic Acid 476473-90-2P, 3-Bromo-2-(6-methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-61-0P,
 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476477-23-3P, 7-Bromo-4-[2-(pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700871-79-0P,
 [2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-yl]boronic acid
 700871-80-3P, 3-(2-Oxopyrrolidin-1-ylimino)-3-pyridin-2-ylpropionic Acid
 Ethyl Ester 700871-81-4P, 3-(6-Methylpyridin-2-yl)-3-(2-oxopyrrolidin-1-
 ylimino)propionic acid ethyl ester 700871-82-5P, 2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic Acid Ethyl Ester
 700871-83-6P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-
 carboxylic Acid 700871-84-7P, 3-Bromo-2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazole 700871-85-8P, 2-(6-Methylpyridin-2-yl)-5,6-
 dihydropyrrolo[1,2-b]pyrazole-3-boronic acid 700871-86-9P,
 Trifluoromethanesulfonic Acid 7-bromoquinolin-4-yl Ester 700871-87-0P,
 7-Bromo-4-iodoquinoline 700871-88-1P, 4,7-Dibromoquinoline
 700873-20-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-1,3,2)dioxaborolan-2-
 yl]phenyl]quinoline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
 modulators)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d ibib abs hitstr

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:273570 CAPLUS Full-text

DOCUMENT NUMBER: 148:417257

TITLE: Optimization of a Dihydropyrrolopyrazole Series of

Transforming Growth Factor- β Type I Receptor

Kinase Domain Inhibitors: Discovery of an Orally

Bioavailable Transforming Growth Factor- β

Receptor Type I Inhibitor as Antitumor Agent


AUTHOR(S): Li, Hong-yu; McMillen, William T.; Heap, Charles R.;
 McCann, Denis J.; Yan, Lei; Campbell, Robert M.;
 Mundla, Sreenivasa R.; King, Chi-Hsin R.; Dierks,
 Elizabeth A.; Anderson, Bryan D.; Britt, Karen S.;
 Huss, Karen L.; Voss, Matthew D.; Wang, Yan; Clawson,
 David K.; Yingling, Jonathan M.; Sawyer, J. Scott

CORPORATE SOURCE: Discovery Chemistry Research and Technology, Drug
 Disposition Research, Cancer Research, Lead
 Optimization Biology, and Chemical Product Research
 and Development, Lilly Research Laboratories, Eli
 Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(7),
 2302-2306

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB In the continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, the authors have discovered a compound (I), which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor I (LY2109761) is representative of a novel series of antitumor agents.


IT 1018352-60-7P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018352-60-7 CAPLUS

CN Quinoline, 7-(2-chloroethoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-15-4P 476474-29-0P 476475-53-3P
 476475-69-1P 476475-73-7P 476475-75-9P
 1018352-70-9P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 476474-15-4 CAPLUS


CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-

3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-73-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-70-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-methyl-2-pyrrolidinyl)propoxy]- (CA INDEX NAME)




IT 476474-11-0P 476474-52-9P 476474-60-9P
476474-62-1P 476475-01-1P 476475-02-2P
476475-44-2P 1018352-73-2P 1018352-76-5P
1018353-32-6P 1018353-35-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476474-11-0 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-52-9 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-60-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 1018352-73-2 CAPLUS

CN Benzoic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 1018352-76-5 CAPLUS

CN Benzamide, 4-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl]- (CA INDEX NAME)




RN 1018353-32-6 CAPLUS

CN Benzonitrile, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 1018353-35-9 CAPLUS

CN Benzamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



IT 476475-90-8P 476475-93-1P 476475-95-3P

476476-79-6P 476476-97-8P 700874-71-1P


1018352-79-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-93-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(ethylthio)- (CA INDEX NAME)




RN 476475-95-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methoxy- (CA INDEX NAME)




RN 476476-79-6 CAPLUS

CN Ethanone, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-97-8 CAPLUS


CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 700874-71-1 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-79-8 CAPLUS
 CN Benzenemethanamine, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




IT 1018353-38-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)
 RN 1018353-38-2 CAPLUS
 CN Benzenecarbothioamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




IT 476473-79-7P 476474-13-2P 476474-40-5P
 476476-80-9P 700874-73-3P 700874-74-4P
 700874-75-5P 1018352-65-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)
 RN 476473-79-7 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-13-2 CAPLUS

CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476476-80-9 CAPLUS

CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-73-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)




RN 700874-74-4 CAPLUS

CN Ethanol, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-75-5 CAPLUS

CN Ethanol, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1-methanesulfonate (CA INDEX NAME)



RN 1018352-65-2 CAPLUS

CN Acetic acid, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, ethyl ester (CA INDEX NAME)




REFERENCE COUNT:

24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 1-9

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:273570 CAPLUS Full-text
DOCUMENT NUMBER: 148:417257
TITLE: Optimization of a Dihydropyrrolopyrazole Series of
Transforming Growth Factor- β Type I Receptor
Kinase Domain Inhibitors: Discovery of an Orally
Bioavailable Transforming Growth Factor- β
Receptor Type I Inhibitor as Antitumor Agent
AUTHOR(S): Li, Hong-yu; McMillen, William T.; Heap, Charles R.;
McCann, Denis J.; Yan, Lei; Campbell, Robert M.;
Mundla, Sreenivasa R.; King, Chi-Hsin R.; Dierks,
Elizabeth A.; Anderson, Bryan D.; Britt, Karen S.;
Huss, Karen L.; Voss, Matthew D.; Wang, Yan; Clawson,
David K.; Yingling, Jonathan M.; Sawyer, J. Scott
CORPORATE SOURCE: Discovery Chemistry Research and Technology, Drug
Disposition Research, Cancer Research, Lead
Optimization Biology, and Chemical Product Research
and Development, Lilly Research Laboratories, Eli
Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2008), 51(7),
2302-2306
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB In the continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, the authors have discovered a compound (I), which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor I (LY2109761) is representative of a novel series of antitumor agents.

IT 1018352-60-7P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018352-60-7 CAPLUS

CN Quinoline, 7-(2-chloroethoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 476474-15-4P 476474-29-0P 476475-53-3P
476475-69-1P 476475-73-7P 476475-75-9P
1018352-70-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476474-15-4 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-73-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-70-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-methyl-2-pyrrolidinyl)propoxy]- (CA INDEX NAME)




IT 476474-11-0P 476474-52-9P 476474-60-9P
 476474-62-1P 476475-01-1P 476475-02-2P
 476475-44-2F 1018352-73-2F 1018352-76-5P
 1018353-32-6P 1018353-35-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476474-11-0 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-52-9 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-60-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 1018352-73-2 CAPLUS

CN Benzoic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 1018352-76-5 CAPLUS

CN Benzamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 1018353-32-6 CAPLUS

CN Benzonitrile, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 1018353-35-9 CAPLUS

CN Benzamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




IT 476475-90-8P 476475-93-1P 476475-95-3P
476476-79-6P 476476-97-8P 700874-71-1P
1018352-79-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-93-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(ethylthio)- (CA INDEX NAME)




RN 476475-95-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methoxy- (CA INDEX NAME)




RN 476476-79-6 CAPLUS

CN Ethanone, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-97-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 700874-71-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-79-8 CAPLUS

CN Benzenemethanamine, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




IT 1018353-38-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018353-38-2 CAPLUS

CN Benzenecarbothioamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



IT 476473-79-7P 476474-13-2P 476474-40-5P

476476-80-9P 700874-73-3P 700874-74-4P


700874-75-5P 1018352-65-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- β type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476473-79-7 CAPLUS

CN Quinoline, 7-[(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-13-2 CAPLUS

CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476476-80-9 CAPLUS

CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-73-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)



RN 700874-74-4 CAPLUS


CN Ethanol, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 700874-75-5 CAPLUS


CN Ethanol, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-

7-quinolinyl]oxy]-, 1-methanesulfonate (CA INDEX NAME)



RN 1018352-65-2 CAPLUS

CN Acetic acid, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:675680 CAPLUS Full-text

DOCUMENT NUMBER: 147:64572

TITLE: Control of intraocular pressure using ALK5 modulation agents

INVENTOR(S): Fleenor, Debra L.; Pang, Iok-Hou; Shepard, Allan R.; Hellberg, Mark R.; Clark, Abbot F.; Klimko, Peter G.

PATENT ASSIGNEE(S): Alcon, Inc., Switz.

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| ----- | ---- | ----- | ----- | ----- |
| WO 2007070866 | A2 | 20070621 | WO 2006-US62151 | 20061215 |
| WO 2007070866 | A3 | 20080103 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, | | | |

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20070142376 A1 20070621 US 2006-611312 20061215

PRIORITY APPLN. INFO.: US 2005-751130P P 20051216

AB The invention discloses an ophthalmic pharmaceutical compn. useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity. The invention also discloses a method for treating glaucoma and controlling intraocular pressure, comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.


IT 737791-20-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(ALK5 modulators for control of intraocular pressure and treatment of glaucoma)

RN 737791-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
(CA INDEX NAME)



L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:173978 CAPLUS Full-text

DOCUMENT NUMBER: 146:229339

TITLE: Preparation of 2-(6-methylpyridin-2-yl)-3-[6-amidoquinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate as a transforming growth factor- β (TGF- β) inhibitor.

INVENTOR(S): Mundla, Sreenivasa Reddy

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 23pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| ----- | ---- | ----- | ----- | ----- |
| WO 2007018818 | A1 | 20070215 | WO 2006-US25377 | 20060629 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, | | | |

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

CA 2616196 A1 20070215 CA 2006-2616196 20060629
EP 1910370 A1 20080416 EP 2006-774280 20060629

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, RS

PRIORITY APPLN. INFO.:

US 2005-701641P P 20050722
WO 2006-US25377 W 20060629


AB Title compd. (I) was prepd. I [prepn. from 4-aminobenzonitrile, Me vinyl
ketone, Me 6-methyl-2-pyridinecarboxylate, and 1- [(diphenylmethylene)amino]-
2-pyrrolidinone given] inhibited TGF- β type I with IC₅₀ = 56 nM.

IT 924898-09-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole
monohydrate as a transforming growth factor- β inhibitor)

RN 924898-09-9 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-
pyrrolo[1,2-b]pyrazol-3-yl]-, hydrate (1:1) (CA INDEX NAME)




● H₂O

IT 700874-72-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole
monohydrate as a transforming growth factor- β inhibitor)

RN 700874-72-2 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-
pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 924898-13-5F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of methylpyridinylamidoquinolinyldihydropyrrolopyrazole monohydrate as a transforming growth factor- β inhibitor)

RN 924898-13-5 CAPLUS

CN 6-Quinolinecarbonitrile, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:393830 CAPLUS Full-text

DOCUMENT NUMBER: 143:90247

TITLE: Complete Inhibition of Anisomycin and UV Radiation but Not Cytokine Induced JNK and p38 Activation by an Aryl-substituted Dihydropyrrolopyrazole Quinoline and Mixed Lineage Kinase 7 Small Interfering RNA

AUTHOR(S): Wang, Xushan; Mader, Mary M.; Toth, John E.; Yu, Xiaohong; Jin, Najia; Campbell, Robert M.; Smallwood, Jeffrey K.; Christe, Michael E.; Chatterjee, Arindam; Goodson, Theodore, Jr.; Vlahos, Chris J.; Matter, William F.; Bloem, Laura J.

CORPORATE SOURCE: Cardiovascular Discovery Research, Lead Optimization Biology, and Discovery Chemistry Research, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Biological Chemistry (2005), 280(19), 19298-19305

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates the pro-apoptotic signaling pathways p38 and JNK. A library of potential kinase inhibitors was screened, and a series of dihydropyrrolopyrazole quinolines was identified as highly potent inhibitors of MLK7 in vitro catalytic activity. Of this series, an aryl-substituted dihydropyrrolopyrazole quinoline (DHP-2) demonstrated an IC₅₀ of 70 nM for inhibition of pJNK formation in COS-7 cell MLK7/JNK cotransfection assays. In stimulated cells, DHP-2 at 200 nM or MLK7 small interfering RNA completely blocked anisomycin and UV induced but had no effect on interleukin-1 β or tumor necrosis factor- α -induced p38 and JNK activation. Addnl., the compound blocked anisomycin and UV-induced apoptosis in COS-7 cells. Heart tissue homogenates from MLK7 transgenic mice treated with DHP-2 at 30 mg/kg had reduced JNK and p38 activation with no apparent effect on ERK activation, demonstrating that this compound can be used to block MLK7-driven MAPK pathway activation in vivo. Taken together, these data demonstrate that MLK7 is the MAPKKK required for modulation of the stress-activated MAPKs downstream of

anisomycin and UV stimulation and that DHP-2 can be used to block MLK7 pathway activation in cells as well as in vivo.

IT 700871-96-1 700871-98-3 700872-04-4
700872-67-9 700872-74-8 700873-01-4
700873-31-0 700874-52-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA)


RN 700871-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-95-0


CMF C26 H20 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-98-3 CAPLUS

CN Phenol, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-97-2


CMF C26 H20 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-04-4 CAPLUS

CN Benzenamine, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-03-3


CMF C26 H21 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 700872-67-9 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-74-8 CAPLUS

CN Benzoic acid, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-73-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-01-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-00-3


CMF C25 H20 N4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700873-31-0 CAPLUS

CN Benzenamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-fluoro- (CA INDEX NAME)



RN 700874-52-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:467896 CAPLUS Full-text

DOCUMENT NUMBER: 141:23528

TITLE: Preparation of substituted pyrrolo[1,2-b]pyrazoles as

INVENTOR(S): mixed lineage kinase modulators
 Chatterjee, Arindam; Goodson, Theodore, Jr.; Mader,
 Mary Margaret; Toth, John Eldon
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|------------------|-----------------|------------|
| WO 2004048383 | A1 | 20040610 | WO 2003-US35036 | 20031112 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2506799 | A1 | 20040610 | CA 2003-2506799 | 20031112 |
| AU 2003298611 | A1 | 20040618 | AU 2003-298611 | 20031112 |
| EP 1567528 | A1 | 20050831 | EP 2003-796362 | 20031112 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006522735 | T | 20061005 | JP 2004-555371 | 20031112 |
| US 20080113977 | A1 | 20080515 | US 2005-535061 | 20050512 |
| PRIORITY APPLN. INFO.: | | | US 2002-428322P | P 20021121 |
| | | | WO 2003-US35036 | W 20031112 |
| OTHER SOURCE(S): | | MARPAT 141:23528 | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1 = H, halo, alkyl; R2 = (un)substituted aryl] are prepared
 For instance, An appropriately substituted 1-[(2,2-
 disubstituted)ethylideneamino]pyrrolidin-2-one is cyclized to 7-bromo-4-[2-
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline. This
 intermediate is coupled to thiophene-2-boronic acid (i-PrOH, K2CO3, (PPh3)4Pd,
 80°, 5 h) to give II. Certain compds. I have an IC50 ≤ 10,000 nM for mixed
 lineage kinase 7 (MLK7). I are useful for the treatment of congestive heart
 disease.

IT 700872-48-6P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic Acid trifluoroacetate
 700872-67-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700874-15-3P,
 [2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-7-yl]benzoylamino]ethyl]carbamic acid tert-butyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
 modulators)

RN 700872-48-6 CAPLUS
 CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-47-5
 CMF C29 H24 N4 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 700872-67-9 CAPLUS
 CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700874-15-3 CAPLUS
 CN Carbamic acid, [2-[[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-68-0P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
 700872-70-4P, 7-(3,5-Bis-trifluoromethylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-72-6P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
 700872-74-8P, 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
 700872-76-0P, 7-(4-Isobutylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-78-2P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenoxy]acetic Acid trifluoroacetate
 700872-80-6P, 7-Benzo[b]thiophene-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-82-8P, 7-Benzofuran-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-84-0P
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-3-yl]quinoline trifluoroacetate 700872-86-2P,
 7-Furan-3-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-88-4P,
 7-(4-Methyl-3-nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-90-8P,
 7-(4-Cyclohexylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate 700872-92-0P,
 7-[4-(Benzo[b]thiophene-3-yl)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-93-1P
 , 7-(3,4-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-94-2P, 4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid
 700872-95-3P, 3-[4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid
 700872-96-4P, 7-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-97-5P,
 7-(4-Methoxyphenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-99-7P, 7-Phenyl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-01-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-2-yl]quinoline trifluoroacetate 700873-02-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)quinoline 700873-03-6P, 7-(4-Chlorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-05-8P,
 7-Furan-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-07-0P 700873-09-2P
 700873-11-6P 700873-13-8P 700873-15-0P
 700873-17-2P 700873-19-4P, 7-Cyclohexyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700873-22-9P 700873-24-1P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]acetic acid trifluoroacetate 700873-26-3P, 7-(4-(Methanesulfonyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-28-5P 700873-30-9P
 700873-32-1P 700873-34-3P, 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]isophthalic acid trifluoroacetate 700873-36-5P 700873-38-7P,
 7-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophene-5-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700873-40-1P 700873-42-3P 700873-45-6P,
 7-(6-Methoxypyridazin-3-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-

b]pyrazol-3-yl]quinoline difluoroacetate 700873-47-8P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
 [pyrimidin-2-yl]quinoline difluoroacetate 700873-49-0P,
 4-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-7-yl]phenyl]butyramide trifluoroacetate 700873-51-4P
 700873-53-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]-7-[pyrimidin-5-yl]quinoline difluoroacetate
 700873-55-8P 700873-57-0P 700873-59-2P,
 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-
 7-yl]thiophene-2-sulfonic acid amide trifluoroacetate 700873-61-6P
 700873-63-8P 700873-64-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide
 700873-65-0P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-66-1P,
 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-
 7-yl]benzenesulfonamide 700873-68-3P 700873-71-8P
 700873-73-0P, 7-Pyrazol-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-75-2P
 700873-76-3P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]piperazine-1-carboxylic acid tert-butyl ester
 700873-78-5P, 7-Piperidin-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-80-9P
 700873-81-0P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid methyl ester
 700873-83-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionamide 700873-85-4P
 700873-88-7P 700873-91-2P 700873-93-4P
 700873-96-7P 700873-98-9P 700874-01-7P
 700874-04-0P 700874-07-3P 700874-09-5P,
 7-[4-(2-Methoxyethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-11-9P
 , 7-[4-(2-Fluoroethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-14-2P
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-
 (2,2,2-trifluoroethoxy)phenyl]quinoline trifluoroacetate
 700874-17-5P, Piperidin-1-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
 700874-18-6P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]thiomorpholin-4-ylmethanone
 700874-20-0P, Morpholin-4-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
 700874-22-2P, N-Carbamoylmethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-
 4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-23-3P
 , N-[2-(Isopropylamino)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-24-4P,
 N-[2-(tert-Butylsulfanyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-26-6P,
 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-7-yl]benzoylamino]propionic Acid Ethyl Ester
 700874-28-8P, N-(1,1-Dioxotetrahydrothiophene-3-yl)-4-[4-[2-
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-
 yl]benzamide 700874-30-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-
 4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]piperidine-1-
 carboxylic acid tert-butyl ester 700874-32-4P
 700874-34-6P, N-(2-(Morpholin-4-yl)ethyl)-4-[4-[2-(pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide
 700874-36-8P, (1,1-Dioxothiophen-4-yl)[4-[4-[2-(pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
 700874-38-0P 700874-40-4P 700874-42-6P,
 N,N-Dimethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-

yl]quinolin-7-yl]benzamide 700874-44-8P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic acid tert-butyl ester 700874-46-0P, N-Methyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-48-2P, N-[2-(Methanesulfonyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-50-6P, N-[(Dimethylamino)methylene]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-52-8P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-55-1P 700874-57-3P 700874-59-5P 700874-61-9P 700874-69-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)


RN 700871-92-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methyl-2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-91-6


CMF C25 H20 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-94-9 CAPLUS

CN Acetamide, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-93-8


CMF C28 H23 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-95-0


CMF C26 H20 N4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700871-98-3 CAPLUS
CN Phenol, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700871-97-2
CMF C26 H20 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-00-0 CAPLUS
CN Phenol, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700871-99-4
CMF C26 H20 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-02-2 CAPLUS

CN Phenol, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-01-1


CMF C26 H20 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-04-4 CAPLUS

CN Benzenamine, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-03-3


CMF C26 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-06-6 CAPLUS

CN Benzenamine, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-05-5


CMF C26 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-10-2 CAPLUS

CN Quinoline, 7-(3-chlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-09-9


CMF C26 H19 Cl N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-12-4 CAPLUS

CN Quinoline, 7-(4-chlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-11-3


CMF C26 H19 Cl N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-14-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-13-5


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-16-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-15-7


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-18-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-17-9


CMF C27 H22 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-20-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-19-1


CMF C27 H23 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-22-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-ethoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-21-5


CMF C28 H24 N4 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700872-24-8 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-ethoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-23-7
CMF C28 H24 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-26-0 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-ethoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-25-9
CMF C28 H24 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-28-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-27-1


CMF C27 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-30-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluoro-3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-29-3


CMF C27 H21 F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-32-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluoro-2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-31-7


CMF C27 H21 F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-34-0 CAPLUS

CN Quinoline, 7-(4-bromophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-33-9


CMF C26 H19 Br N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-36-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(ethylthio)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-35-1


CMF C28 H24 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-38-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

[4-(methylthio)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-37-3


CMF C27 H22 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-40-8 CAPLUS

CN Benzonitrile, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-39-5


CMF C27 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-42-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-indol-5-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-41-9


CMF C28 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-44-2 CAPLUS

CN Ethanone, 1-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-43-1


CMF C28 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-46-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 4'-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 700872-45-3


CMF C33 H25 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-50-0 CAPLUS

CN Quinoline, 7-(3,5-dichlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-49-7


CMF C26 H18 Cl2 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-52-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxy-3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-51-1


CMF C28 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-54-4 CAPLUS

CN Benzenamine, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-53-3


CMF C27 H23 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-56-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-55-5


CMF C25 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-58-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-57-7


CMF C25 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-60-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-59-9


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-62-4 CAPLUS

CN Acetamide, N-[3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-61-3


CMF C28 H23 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-64-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methylsulfinyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-63-5


CMF C27 H22 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-66-8 CAPLUS

CN Quinoline, 7-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-65-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-68-0 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-67-9


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-70-4 CAPLUS

CN Quinoline, 7-[3,5-bis(trifluoromethyl)phenyl]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-69-1


CMF C28 H18 F6 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-72-6 CAPLUS

CN Benzoic acid, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-71-5


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-74-8 CAPLUS

CN Benzoic acid, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-73-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-76-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-methylpropyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-75-9


CMF C30 H28 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-78-2 CAPLUS

CN Acetic acid, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-77-1


CMF C28 H22 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-80-6 CAPLUS

CN Quinoline, 7-benzo[b]thien-2-yl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-79-3


CMF C28 H20 N4 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700872-82-8 CAPLUS
 CN Quinoline, 7-(2-benzofuranyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-81-7
 CMF C28 H20 N4 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700872-84-0 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 700872-83-9
 CMF C24 H18 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-86-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-furanyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-85-1


CMF C24 H18 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-88-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(4-methyl-3-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-87-3


CMF C27 H21 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-90-8 CAPLUS

CN Quinoline, 7-(4-cyclohexylphenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-89-5


CMF C32 H30 N4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700872-92-0 CAPLUS
 CN Quinoline, 7-(4-benzo[b]thien-3-ylphenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-91-9
 CMF C34 H24 N4 S




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700872-93-1 CAPLUS
 CN Quinoline, 7-(3,4-dichlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700872-94-2 CAPLUS
 CN Benzoic acid, 4-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-95-3 CAPLUS

CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-96-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluorophenyl)- (CA INDEX NAME)



RN 700872-97-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxyphenyl)- (CA INDEX NAME)



RN 700872-99-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CRN 700872-98-6
CMF C27 H22 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-01-4 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700873-00-3
CMF C25 H20 N4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-02-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)- (CA INDEX NAME)



RN 700873-03-6 CAPLUS

CN Quinoline, 7-(4-chlorophenyl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700873-05-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-furanyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-04-7


CMF C24 H18 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-07-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thiazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-06-9


CMF C23 H17 N5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-09-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyrazinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-08-1


CMF C24 H18 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-11-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-10-5


CMF C25 H19 N5



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-13-8 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrrol-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 700873-12-7
 CMF C24 H19 N5



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700873-15-0 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-indol-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 700873-14-9
 CMF C28 H21 N5



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 700873-17-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrrol-3-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-16-1


CMF C24 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-19-4 CAPLUS

CN Quinoline, 7-cyclohexyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-18-3


CMF C26 H26 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-22-9 CAPLUS

CN Ethanol, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-quinolinyl]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-21-8


CMF C28 H24 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-24-1 CAPLUS

CN Benzeneacetic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-23-0


CMF C28 H22 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-26-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methanesulfonyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-25-2


CMF C27 H22 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700873-28-5 CAPLUS


CN Benzeneethanamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-

b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-27-4


CMF C28 H25 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-30-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-29-6


CMF C27 H22 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-32-1 CAPLUS

CN Benzenamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-fluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-31-0


CMF C26 H20 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-34-3 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-33-2


CMF C28 H20 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-36-5 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 1,3-dimethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-35-4


CMF C30 H24 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-38-7 CAPLUS

CN Quinoline, 7-(1,3-dihydro-2,2-dioxidobenzo[c]thien-5-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-37-6


CMF C28 H22 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-40-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:3)
(CA INDEX NAME)

CM 1

CRN 700873-39-8


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-42-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(5-fluoro-2-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-41-2


CMF C25 H18 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-45-6 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(6-methoxy-3-pyridazinyl)quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-44-5


CMF C25 H20 N6 O



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-47-8 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyrimidinyl)quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-46-7


CMF C24 H18 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-49-0 CAPLUS

CN Benzenebutanamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-48-9


CMF C30 H27 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-51-4 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 7-(1H-benzimidazol-2-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-50-3


CMF C27 H20 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-53-6 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(5-pyrimidinyl)quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-52-5


CMF C24 H18 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-55-8 CAPLUS

CN Benzenamine, 2-chloro-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-54-7


CMF C26 H20 Cl N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-57-0 CAPLUS

CN Phenol, 2-chloro-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-6-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-56-9


CMF C26 H18 Cl F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-59-2 CAPLUS

CN 2-Thiophenesulfonamide, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-58-1


CMF C24 H19 N5 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-61-6 CAPLUS

CN Phenol, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2,3-difluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-60-5


CMF C26 H18 F2 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700873-63-8 CAPLUS


CN 2-Benzothiazolamine, 6-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-

b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 700873-62-7


CMF C27 H20 N6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700873-64-9 CAPLUS

CN Benzenesulfonamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-65-0 CAPLUS

CN Benzenesulfonamide, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700873-66-1 CAPLUS

CN Benzenesulfonamide, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-68-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-imidazol-1-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-67-2


CMF C23 H18 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-71-8 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-1,2,4-triazol-1-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 700873-70-7
 CMF C22 H17 N7



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700873-73-0 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrazol-1-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700873-72-9
 CMF C23 H18 N6



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 700873-75-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-1,2,3-triazol-1-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-74-1


CMF C22 H17 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 700873-76-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 700873-78-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(1-piperidinyl)- (CA INDEX NAME)




RN 700873-80-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 700873-81-0 CAPLUS

CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)



RN 700873-83-2 CAPLUS

CN Benzenepropanamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-85-4 CAPLUS

CN Ethanamine, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-84-3


CMF C30 H29 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-88-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(4-morpholinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-87-6


CMF C32 H31 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-91-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-90-1


CMF C33 H33 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-93-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-92-3


CMF C32 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-96-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(1-piperidinyl)propoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-95-6


CMF C34 H35 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-98-9 CAPLUS

CN 1-Propanamine, 3-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-97-8


CMF C31 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-01-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(4-morpholinyl)propoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-00-6


CMF C33 H33 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-04-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-03-9


CMF C33 H33 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-07-3 CAPLUS

CN Acetamide, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-06-2


CMF C28 H23 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-09-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-methoxyethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-08-4


CMF C29 H26 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-11-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-fluoroethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-10-8


CMF C28 H23 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-14-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2,2,2-trifluoroethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-13-1


CMF C28 H21 F3 N4 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700874-17-5 CAPLUS

CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-1-piperidinyl- (CA INDEX NAME)




RN 700874-18-6 CAPLUS

CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-4-thiomorpholinyl- (CA INDEX NAME)




RN 700874-20-0 CAPLUS

CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 700874-22-2 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700874-23-3 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-[(1-methylethyl)amino]ethyl]- (CA INDEX NAME)




RN 700874-24-4 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-[(1,1-dimethylethyl)thio]ethyl]- (CA INDEX NAME)




RN 700874-26-6 CAPLUS

CN β -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 700874-28-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)



RN 700874-30-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 700874-32-4 CAPLUS


CN L-Lysine, N2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-N6-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-34-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 700874-36-8 CAPLUS


CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl](1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 700874-38-0 CAPLUS

CN D-Cysteine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-S-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 700874-40-4 CAPLUS


CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-42-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 700874-44-8 CAPLUS

CN β -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 700874-46-0 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-methyl- (CA INDEX NAME)




RN 700874-48-2 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 700874-50-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[(dimethylamino)methylene]- (CA INDEX NAME)



RN 700874-52-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700874-55-1 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-54-0


CMF C29 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700874-57-3 CAPLUS


CN Benzamide, N-[(1S)-5-amino-1-methylpentyl]-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-56-2

CMF C33 H34 N6 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-59-5 CAPLUS
 CN D-Cysteine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-S-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700874-58-4
 CMF C31 H27 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 700874-61-9 CAPLUS
 CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-60-8
 CMF C32 H27 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-69-7 CAPLUS

CN β -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-68-6


CMF C30 H25 N5 O3




CM 2

CRN 76-05-1


CMF C2 H F3 O2




IT 700872-01-1, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)
 RN 700872-01-1 CAPLUS
 CN Phenol, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



IT 476474-61-0P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-23-3P, 7-Bromo-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-20-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]quinoline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)
 RN 476474-61-0 CAPLUS
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-23-3 CAPLUS
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 700873-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:467895 CAPLUS Full-text

DOCUMENT NUMBER: 141:23527

TITLE: Preparation of quinolinyl pyrrolopyrazoles as TGF- β signal transduction inhibitors

INVENTOR(S): Beight, Douglas Wade; Sawyer, Jason Scott; Yingling, Jonathan Michael

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004048382 | A1 | 20040610 | WO 2003-US32747 | 20031110 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2501322 | A1 | 20040610 | CA 2003-2501322 | 20031110 |
| AU 2003291643 | A1 | 20040618 | AU 2003-291643 | 20031110 |
| BR 2003015337 | A | 20050816 | BR 2003-15337 | 20031110 |
| EP 1565471 | A1 | 20050824 | EP 2003-768531 | 20031110 |

EP 1565471 B1 20061004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1714090 A 20051228 CN 2003-80103840 20031110
JP 2006514012 T 20060427 JP 2004-555329 20031110
AT 341550 T 20061015 AT 2003-768531 20031110
NZ 538942 A 20070126 NZ 2003-538942 20031110
ES 2273046 T3 20070501 ES 2003-768531 20031110
US 20060040983 A1 20060223 US 2005-531237 20050413
US 7265225 B2 20070904
ZA 2005003121 A 20060726 ZA 2005-3121 20050418
MX 2005PA05432 A 20050803 MX 2005-PA5432 20050520
IN 2005KN00943 A 20060421 IN 2005-KN943 20050520
NO 2005003045 A 20050621 NO 2005-3045 20050621
HK 1081948 A1 20070504 HK 2006-102038 20060216
US 20080027102 A1 20080131 US 2007-782659 20070725
PRIORITY APPLN. INFO.: US 2002-428893P P 20021122
WO 2003-US32747 W 20031110
US 2005-531237 A1 20050413

GI




AB The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (preps. given), was given. The compds. I and II inhibit the TGF- β type I receptor kinase domain with IC₅₀ of <20 μ M, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/US02/11884. The pharmaceutical composition comprising the compound II is claimed.

IT 700874-71-1P 700874-72-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolinyl pyrrolopyrazoles as TGF- β signal transduction inhibitors)

RN 700874-71-1 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 700874-72-2 CAPLUS
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-11-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinolinyl pyrrolopyrazoles as TGF- β signal transduction inhibitors)


RN 476474-11-0 CAPLUS
 CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-52-9P 476475-44-2P 700874-73-3P
 700874-74-4P 700874-75-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of quinolinyl pyrrolopyrazoles as TGF- β signal transduction inhibitors)

RN 476474-52-9 CAPLUS
 CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 700874-73-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)




RN 700874-74-4 CAPLUS

CN Ethanol, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-75-5 CAPLUS

CN Ethanol, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1-methanesulfonate (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:465519 CAPLUS Full-text
 DOCUMENT NUMBER: 141:190720
 TITLE: Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines
 AUTHOR(S): Li, Hong-Yu; Wang, Yan; Yan, Lei; Campbell, Robert M.; Anderson, Bryan D.; Wagner, Jill R.; Yingling, Jonathan M.
 CORPORATE SOURCE: Discovery Chemistry Research, Lilly Corporate Center, A Division of Eli Lilly and Company, Lilly Research Laboratory, Indianapolis, IN, 46285, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3585-3588
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:190720
 GI



AB A novel series of 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines was synthesized and their T β R-1 inhibitory, p38 MAPK inhibitory, and T β R-1-dependent cellular activity were evaluated. Compound I was found to be a highly potent in the enzyme assay and T β R-1-dependent cellular assays. In addition, dimer (II), with a urea linker, shows a similar enzyme and cellular activity despite a bulky substitution.


IT 476477-22-2P 476477-26-6P 476477-37-9P
476477-39-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as potent transforming growth factor beta type I receptor kinase domain inhibitor)


RN 476477-22-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-26-6 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 476477-37-9 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)



RN 476477-39-1 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




IT 476477-27-7P 476477-28-8P 476477-29-9P
476477-32-4P 476477-36-8P 476477-38-0P
476477-41-5P 476477-94-8P 476477-95-9P
737765-68-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as
potent transforming growth factor beta type I receptor kinase domain
inhibitor)


RN 476477-27-7 CAPLUS

CN Propanamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 476477-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-29-9 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-32-4 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-(dimethylamino)ethyl)- (CA INDEX NAME)




RN 476477-36-8 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(3-(dimethylamino)propyl)- (CA INDEX NAME)




RN 476477-38-0 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 476477-41-5 CAPLUS

CN Urea, N,N'-bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-94-8 CAPLUS

CN 2-Oxazolidinone, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-95-9 CAPLUS

CN 2-Imidazolidinone, 1-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 737765-68-3 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)



IT 476477-23-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as

potent transforming growth factor beta type I receptor kinase domain inhibitor)

RN 476477-23-3 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 737765-69-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as potent transforming growth factor beta type I receptor kinase domain inhibitor)

RN 737765-69-4 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(diphenylmethylene)- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:465518 CAPLUS Full-text

DOCUMENT NUMBER: 141:190719

TITLE: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor- β type I receptor kinase domain

AUTHOR(S): Sawyer, J. Scott; Beight, Douglas W.; Britt, Karen S.; Anderson, Bryan D.; Campbell, Robert M.; Goodson, Theodore; Herron, David K.; Li, Hong-Yu; McMillen, William T.; Mort, Nicholas; Parsons, Stephen; Smith, Edward C. R.; Wagner, Jill R.; Yan, Lei; Zhang, Faming; Yingling, Jonathan M.


CORPORATE SOURCE: Discovery Chemistry Research and Technology, Lilly Corporate Center, The Lilly Research Laboratories, Indianapolis, IN, 46285, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3581-3584


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:190719
 GI



I



II

AB We have expanded our previously reported series of pyrazole-based inhibitors of the TGF- β type I receptor kinase domain (T β R-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogs. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, Ph substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray anal. of compds. I and II, two potent examples of this new series, with the T β R-I receptor kinase domain.


IT 737791-20-7P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(crystal structure; preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- β type I receptor kinase domain)

RN 737791-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476475-11-3P 476475-12-4P 476475-13-5P

476475-77-1P 476476-39-8P 737791-21-8P


737791-22-9P 737791-23-0P 737791-24-1P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- β type I receptor kinase domain)


RN 476475-11-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-methylethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-12-4 CAPLUS

CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-13-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476475-77-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylthio)- (CA INDEX NAME)



RN 476476-39-8 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(ethylsulfonyl)- (CA INDEX NAME)




RN 737791-21-8 CAPLUS

CN Quinoline, 4-[2-(5-fluoro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-22-9 CAPLUS

CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-23-0 CAPLUS

CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 737791-24-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:906238 CAPLUS Full-text
 DOCUMENT NUMBER: 138:4598
 TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors
 INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.
 SOURCE: PCT Int. Appl., 305 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2002094833 | A1 | 20021128 | WO 2002-US11884 | 20020513 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2446820 | A1 | 20021128 | CA 2002-2446820 | 20020513 |
| AU 2002339268 | A1 | 20021203 | AU 2002-339268 | 20020513 |
| AU 2002339268 | B2 | 20070531 | | |
| EP 1397364 | A1 | 20040317 | EP 2002-744115 | 20020513 |
| EP 1397364 | B1 | 20070725 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002009939 | A | 20040330 | BR 2002-9939 | 20020513 |
| CN 1511157 | A | 20040707 | CN 2002-810508 | 20020513 |
| JP 2004535404 | T | 20041125 | JP 2002-591506 | 20020513 |
| HU 2004000451 | A2 | 20041228 | HU 2004-451 | 20020513 |
| NZ 528525 | A | 20051028 | NZ 2002-528525 | 20020513 |
| CN 1951939 | A | 20070425 | CN 2006-10094674 | 20020513 |

| | | | | |
|------------------------|-----------------|----------|-----------------|-------------|
| AT 368041 | T | 20070815 | AT 2002-744115 | 20020513 |
| ES 2289116 | T3 | 20080201 | ES 2002-744115 | 20020513 |
| IN 2003KN01359 | A | 20060317 | IN 2003-KN1359 | 20031022 |
| ZA 2003008546 | A | 20050131 | ZA 2003-8546 | 20031031 |
| US 20040106604 | A1 | 20040603 | US 2003-477111 | 20031106 |
| US 7087626 | B2 | 20060808 | | |
| MX 2003PA10630 | A | 20040309 | MX 2003-PA10630 | 20031119 |
| NO 2003005193 | A | 20031121 | NO 2003-5193 | 20031121 |
| HK 1064375 | A1 | 20080206 | HK 2004-107054 | 20040915 |
| PRIORITY APPLN. INFO.: | | | US 2001-293464P | P 20010524 |
| | | | CN 2002-810508 | A3 20020513 |
| | | | WO 2002-US11884 | W 20020513 |
| OTHER SOURCE(S): | MARPAT 138:4598 | | | |
| GI | | | | |




AB Title compds. I [R¹ = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R² = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R³ = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared For instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC₅₀ < 20.00 μM for the TGF-β type I receptor.

IT 476477-99-3F, (R)-4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476478-00-9F, (S)-4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-β signal transduction inhibitors)

RN 476477-99-3 CAPLUS

CN Quinoline, 4-[(5R)-5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476478-00-9 CAPLUS

CN Quinoline, 4-[(5S)-5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 476473-79-7P, 7-(3-Chloropropoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-92-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid methyl ester 476473-93-5P, 6-[3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridine-2-carboxylic acid dihydrochloride 476473-94-6P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionic acid 476474-03-0P, [2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476474-11-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476474-25-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid 476474-31-4P, 6-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-37-0P, 4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-40-5P, 7-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-41-6P, 7-Benzyloxy-6-methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-61-0P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-13-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-27-1P, 6-[3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridine-2-carboxylic acid methyl ester 476475-29-3P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]acrylic acid methyl ester 476475-43-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid


methyl ester 476475-44-2P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid methyl ester 476475-52-2P, 3-[[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propylamine 476475-79-3P, 7-Benzylsulfanyl-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-80-6P, 3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]sulfanyl]propan-1-ol 476476-34-3P 476476-47-8P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylic acid methyl ester 476476-85-4P, N,N-Dimethyl-3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]benzamide 476477-22-2P, [4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]amine 476477-39-1P, [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid 2-hydroxyethyl ester 476477-46-0P, 7-Bromo-4-(4-chloro-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-49-3P, 3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-ol 476477-64-2P, N,N-Dimethyl-3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]thiobenzamide 476477-69-7P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionic acid methyl ester 476477-81-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-amino-1,1-dimethylethyl)amide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476473-79-7 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476473-92-4 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476473-93-5 CAPLUS


CN 2-Pyridinecarboxylic acid, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 476473-94-6 CAPLUS

CN 7-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-03-0 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)




RN 476474-11-0 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-25-6 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-31-4 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-37-0 CAPLUS

CN Quinoline, 4-[5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-41-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy-7-(phenylmethoxy)- (CA INDEX NAME)




RN 476474-61-0 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-13-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-27-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 476475-29-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinyl]-, methyl ester (CA INDEX NAME)




RN 476475-43-1 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-52-2 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476475-79-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(phenylmethyl)thio]- (CA INDEX NAME)




RN 476475-80-6 CAPLUS

CN 1-Propanol, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]thio]- (CA INDEX NAME)




RN 476476-34-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476476-47-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)




RN 476476-85-4 CAPLUS

CN Benzamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-22-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-39-1 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




RN 476477-46-0 CAPLUS


CN Quinoline, 7-bromo-4-[4-chloro-5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-49-3 CAPLUS
 CN 4H-Pyrrolo[1,2-b]pyrazol-4-ol, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-64-2 CAPLUS
 CN Benzenecarbothioamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 476477-69-7 CAPLUS
 CN 7-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476477-81-3 CAPLUS
 CN 7-Quinolinecarboxamide, N-(2-amino-1,1-dimethylethyl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-51-8P, 4-[5-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-52-9P, 6-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-53-0P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-trifluoromethylquinoline 476474-60-9P, 8-Fluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-62-1P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-trifluoromethoxyquinoline 476474-63-2P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-trifluoromethylquinoline 476474-64-3P, 7-Methoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-66-5P, [3-(7-Bromoquinolin-4-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476474-67-6P, 4-[2-(6-Chloropyridin-2-yl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-68-7P, 4-[2-(6-Ethoxypyridin-2-yl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-69-8P, (S)-4-[6-Benzoyloxymethyl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-chloroquinoline 476474-70-1P, (S)-4-[6-Benzoyloxymethyl-2-(6-chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-71-2P, 4-[2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-5-yl]benzoic acid ethyl ester 476474-88-1P, 4-[2-(Quinolin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-90-5P, 4-[5-(4-Fluorophenyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-91-6P, 4-(6-Hydroxymethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-93-8P, 4-[4-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-94-9P, 4-[5-Benzyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-96-1P, 4-(5-Phenethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-97-2P, 4-[5-Phenyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-01-1P, 2-Chloro-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-02-2P, 6,8-Dimethoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-03-3P, 4-[2-(6-Bromopyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-04-4P, 6,8-Dimethoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-10-2P, 4-[2-(6-Propylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-11-3P, 4-[2-(6-Isopropylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-12-4P, 4-[2-(6-Ethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-18-0P, 4-[2-(4-Chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-21-5P, 4-[5-(3-Methoxyphenyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-25-9P, 6,7-Difluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline

476475-26-0P, 6,7-Dimethoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-35-1P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-37-3P, 6-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-38-4P, 6-Benzo[1,3]dioxol-5-yl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-39-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(thiophen-2-yl)quinoline 476475-40-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-phenylquinoline 476475-45-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid methyl ester 476475-47-5P, Dimethyl [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]amine 476475-48-6P, [3-[6-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydropyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]dimethylamine 476475-49-7P, ((Cyclopropyl)methyl) propyl [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476475-50-0P, Diethyl [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-51-1P, Ethyl methyl [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-53-3P, 7-[3-(4-Methylpiperazin-1-yl)propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-54-4P, Benzyl methyl [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-55-5P, 7-(3-(Piperidin-1-yl)propoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-56-6P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinoline 476475-57-7P, 7-(3-(Azepan-1-yl)propoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-58-8P, 7-(3-(Imidazol-1-yl)propoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-59-9P, 7-(3-(Pyrazol-1-yl)propoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-60-2P, 1'-[3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl][1,4']bipiperidinyl 476475-61-3P, Cyclopropyl 1-methylpiperidin-4-yl [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476475-62-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-[1,2,3-triazol-1-yl]propoxy]quinoline 476475-63-5P, Dimethyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-64-6P, Diethyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-65-7P, (Cyclopropylmethyl) propyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-67-9P, Ethyl methyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-69-1P, Dimethyl [2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]ethyl]amine 476475-71-5P, Diethyl [2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]ethyl]amine 476475-72-6P, 7-(2-(Piperidin-1-yl)ethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-73-7P, Ethyl methyl [2-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]ethyl]amine 476475-74-8P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(2-

(pyrrolidin-1-yl)ethoxy)quinoline 476475-75-9P,
7-[2-(4-Methylpiperazin-1-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-76-0P,
7-Methylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-77-1P, 7-Ethylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-78-2P,
6-Methylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-81-7P, Dimethyl
[2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]sulfanyl]ethyl]amine 476475-82-8P, Dimethyl
[[6-[3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridin-2-yl]methyl]amine 476475-83-9P, 7-(2-Propoxyethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
476475-86-2P, 3-[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]oxazolidin-2-one
476475-87-3P, 1-[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]imidazolidin-2-one
476475-88-4P, 3-[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]-3H-benzoxazol-2-one
476475-90-8P, 4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(pyrrolidin-1-yl)quinoline 476475-91-9P,
2-Phenylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-92-0P, 2-Morpholin-4-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
476475-93-1P, 2-Ethylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-94-2P, Phenyl
[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-2-yl]amine 476475-95-3P, 2-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-96-4P,
2-Ethoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-97-5P, 4-[2-(6-Phenylsulfanylpiperidin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-98-6P,
Phenyl[6-(3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)pyridin-2-yl]amine 476475-99-7P, 4-[2-[6-(4-Methoxyphenyl)pyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-00-3P, 4-[2-(6-Phenylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-01-4P,
4-[2-(6-Morpholin-4-ylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-02-5P, 4-[2-(6-Pyrrolidin-1-ylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-03-6P,
4-[2-(6-Methoxypyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-04-7P, 7-Benzoyloxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
476476-05-8P, 2-[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]isoindole-1,3-dione
476476-06-9P, 7-(3-Fluoropropoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-07-0P,
7-(3-Chloropropoxy)-6-methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-08-1P,
7-(3-Chloropropoxy)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-10-5P, N,N-Diethyl-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-11-6P, (R)-7-[2-(2-Methylpyrrolidin-2-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-14-9P, 7-(1-Methylpiperidin-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-15-0P, 7-((3-Dimethylamino-2-methylpropyl)oxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-16-1P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-propoxyquinoline 476476-17-2P,

4-[6-Benzylloxymethyl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-18-3P, [[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetic acid methyl ester 476476-19-4P, 7-Isopropoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-20-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(morpholin-4-yl)propoxy]quinoline 476476-23-0P, 2-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]acetamide 476476-24-1P, 7-(5-Phenyl[1,2,4]oxadiazol-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-25-2P, 7-(2,2-Difluorobenzo[1,3]dioxol-5-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-26-3P, (S)-7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-27-4P, 5-[[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]methyl]pyrrolidin-2-one 476476-28-5P, 4-(6-Phenoxymethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-29-6P, 4-(6-Methylene-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-31-0P, 7-((1-Methylpiperidin-2-yl)methoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline hydrochloride 476476-32-1P 476476-33-2P, 7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline hydrochloride 476476-35-4P, 7-Methanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-38-7P, 6-Methanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-39-8P, 7-Ethanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-40-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(pyrimidine-2-sulfonyl)propoxy]quinoline 476476-41-2P, 7-[3-((1-Methyl-1H-imidazol-2-yl)sulfonyl)propoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-42-3P, 7-[3-(4-Chlorobenzenesulfonyl)propoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-43-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(((pyridin-2-yl)methane)sulfonyl)propoxy]quinoline 476476-44-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(((pyridin-2-yl)methane)sulfinyl)propoxy]quinoline 476476-46-7P 476476-48-9P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]-1-(piperidin-1-yl)propenone 476476-49-0P, N,N-Dimethyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylamide 476476-50-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-vinylquinoline 476476-51-4P, 4-[2-(6-Benzylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-52-5P, 7-Benzyl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-53-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ethyl ester 476476-54-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid 476476-55-8P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylic acid 476476-56-9P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid cyclopentylamide 476476-57-0P, 4-[2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-5-yl]benzoic acid 476476-58-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-(morpholin-4-yl)ethyl)amide 476476-59-2P,

4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid [2-(1H-imidazol-4-yl)ethyl]amide 476476-60-5P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-methylaminoethyl)amide 476476-61-6P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-methylaminopropyl)amide 476476-62-7P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-dimethylaminoethyl)amide 476476-63-8P,
 (4-Methylpiperazin-1-yl)[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]methanone 476476-64-9P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid cyclobutylamide 476476-65-0P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid cyclopropylamide 476476-66-1P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (1-ethylpropyl)amide 476476-67-2P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ethylamide 476476-68-3P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid isobutylamide 476476-69-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid tert-butylamide 476476-70-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid isopropylamide 476476-71-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid propylamide 476476-72-9P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-methylbutyl)amide 476476-73-0P 476476-74-1P 476476-75-2P 476476-76-3P 476476-77-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-4-ylmethyl)amide 476476-78-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-3-ylmethyl)amide 476476-79-6P, 1-(4-Methylpiperazin-1-yl)-2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]ethanone 476476-81-0P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-2-ylmethyl)amide 476476-82-1P, 6-(3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)pyridine-2-carboxylic acid amide 476476-83-2P, N-(2-Dimethylaminoethyl)-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-84-3P, N-(2-Dimethylaminoethyl)-N-methyl-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-86-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid amide 476476-89-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ((2-dimethylaminoethyl)methyl)amide 476476-91-2P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid [[3-(dimethylamino)propyl]methyl]amide 476476-93-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid dimethylamide 476476-94-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid methylamide 476476-95-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid N-(pyridin-2-yl)amide 476476-96-7P, N-(2,2-Dimethylaminoethyl)-N-methyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476476-97-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 476476-98-9


P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (3-dimethylaminopropyl)amide 476476-99-0P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (2-(morpholin-4-yl)ethyl)amide 476477-00-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-(piperidinyl)ethyl)amide 476477-01-7P, N-(2-Dimethylaminoethyl)-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-02-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-(morpholin-4-yl)propyl)amide 476477-03-9P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-04-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 476477-05-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid [2-(morpholin-4-yl)ethyl]amide 476477-06-2P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid 476477-07-3P 476477-08-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid amide 476477-09-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (3-methylaminopropyl)amide 476477-10-8P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (2-hydroxyethyl)amide 476477-11-9P 476477-12-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid hydroxyamide 476477-13-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-aminoethyl)amide 476477-14-2P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-hydroxyethyl)amide 476477-15-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid amide 476477-16-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ((2-dimethylaminoethyl)methyl)amide 476477-17-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid amide 476477-18-6P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid methylamide 476477-19-7P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid dimethylamide 476477-20-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid [3-(dimethylamino)propyl]amide 476477-21-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid diethylamide 476477-24-4P 476477-25-5P 476477-26-6P, 2-(Dimethylamino)-N-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-27-7P, 3-Dimethylamino-N-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-28-8P, N-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]methanesulfonamide 476477-29-9P, N-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-31-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid [2-dimethylamino-1-methylethyl]amide 476477-32-4P, N-(2-Dimethylaminoethyl)-N'-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]urea 476477-33-5P, N-[3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]propyl]methanesulfonamide 476477-34-6P, 1-Methyl-1H-imidazole-4-sulfonic acid [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-

4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]propyl]amide
 476477-35-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid
 (2-dimethylamino-1-methylethyl)amide 476477-36-8P,
 N-(3-Dimethylaminopropyl)-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]urea 476477-37-9P,
 N-(2-Hydroxyethyl)-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]urea 476477-38-0P,
 [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-
 yl]carbamic acid methyl ester 476477-40-4P, [4-[2-(Pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid
 2-methoxyethyl ester 476477-41-5P, N,N'-Bis[4-(2-(pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]urea
 476477-42-6P, Dimethylcarbamic acid 4-[2-(pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl ester
 476477-43-7P, 7-Bromo-2-isopropyl-4-(2-(pyridin-2-yl)-5,6-dihydro-
 4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-44-8P,
 2-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-6-yl]propan-2-ol 476477-45-9P, 7-((3-
 Chloropropyl)sulfanyl)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinoline 476477-47-1P, 8-Chloro-4-(2-(pyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol
 476477-48-2P, 8-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol 476477-50-6P,
 7-Bromo-4-[4-methoxy-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
 3-yl]quinoline 476477-51-7P, [3-(7-Bromoquinolin-4-yl)-2-
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-yl]methylamine
 476477-53-9P, 3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-
 dihydropyrrolo[1,2-b]pyrazol-4-one 476477-54-0P,
 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-
 7-yloxy]benzonitrile 476477-56-2P, 3-[4-(2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]benzamide
 476477-58-4P, 7-(6-Methylpyridazin-3-yloxy)-4-[2-(pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-60-8P
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4-
 (pyrimidin-2-yl)piperazin-1-yl)butoxy]quinoline 476477-65-3P,
 Dimethyl[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-7-yloxy]benzyl]amine 476477-66-4P,
 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-
 quinolin-2-one 476477-67-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476474-51-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-52-9 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-53-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 476474-60-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476474-63-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(trifluoromethyl)- (CA INDEX NAME)




RN 476474-64-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-66-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-67-6 CAPLUS

CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-68-7 CAPLUS
 CN Quinoline, 4-[2-(6-ethoxy-2-pyridinyl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-69-8 CAPLUS
 CN Quinoline, 7-chloro-4-[(6S)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-70-1 CAPLUS
 CN Quinoline, 4-[(6S)-2-(6-chloro-2-pyridinyl)-5,6-dihydro-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-71-2 CAPLUS
 CN Benzoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-5-yl]-, ethyl ester (CA INDEX NAME)




RN 476474-88-1 CAPLUS

CN Quinoline, 2-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-
(CA INDEX NAME)




RN 476474-90-5 CAPLUS

CN Quinoline, 4-[5-(4-fluorophenyl)-5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
(CA INDEX NAME)




RN 476474-91-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(2-pyridinyl)-3-(4-quinolinyl)-
(CA INDEX NAME)




RN 476474-93-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-4-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
(CA INDEX NAME)




RN 476474-94-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-(phenylmethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-(2-phenylethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-97-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-phenyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-03-3 CAPLUS

CN Quinoline, 4-[2-(6-bromo-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-04-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-10-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-propyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-11-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-methylethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-12-4 CAPLUS

CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-18-0 CAPLUS

CN Quinoline, 4-[2-(4-chloro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-21-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-(3-methoxyphenyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-25-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,7-difluoro- (CA INDEX NAME)




RN 476475-26-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 476475-35-1 CAPLUS

CN Quinoline, 6,7-dichloro-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-37-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 476475-38-4 CAPLUS

CN Quinoline, 6-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-39-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(2-thienyl)- (CA INDEX NAME)




RN 476475-40-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-phenyl- (CA INDEX NAME)




RN 476475-45-3 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-47-5 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-48-6 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-49-7 CAPLUS

CN Cyclopropanemethanamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-propyl- (CA INDEX NAME)




RN 476475-50-0 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-51-1 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 476475-54-4 CAPLUS

CN Benzenemethanamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)




RN 476475-55-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 476475-56-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




RN 476475-57-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(hexahydro-1H-azepin-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-58-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-imidazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-59-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-pyrazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-60-2 CAPLUS

CN Quinoline, 7-(3-[1,4'-bipiperidin]-1'-ylpropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-61-3 CAPLUS

CN 4-Piperidinamine, N-cyclopropyl-N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1-methyl- (CA INDEX NAME)



RN 476475-62-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-1,2,3-triazol-1-yl)propoxy]- (CA INDEX NAME)



RN 476475-63-5 CAPLUS


CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-

b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-64-6 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-65-7 CAPLUS

CN Cyclopropanemethanamine, N-[3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-propyl- (CA INDEX NAME)




RN 476475-67-9 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-71-5 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-72-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 476475-73-7 CAPLUS


CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 476475-74-8 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 476475-76-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(methylthio)- (CA INDEX NAME)




RN 476475-77-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylthio)- (CA INDEX NAME)




RN 476475-78-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(methylthio)- (CA INDEX NAME)




RN 476475-81-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]thio]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-82-8 CAPLUS

CN 2-Pyridinemethanamine, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-83-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-propoxyethoxy)- (CA INDEX NAME)




RN 476475-86-2 CAPLUS

CN 2-Oxazolidinone, 3-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-87-3 CAPLUS

CN 2-Imidazolidinone, 1-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-88-4 CAPLUS

CN 2(3H)-Benzoxazolone, 3-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-91-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(phenylthio)- (CA INDEX NAME)




RN 476475-92-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 476475-93-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(ethylthio)- (CA INDEX NAME)




RN 476475-94-2 CAPLUS

CN 2-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-phenyl- (CA INDEX NAME)




RN 476475-95-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methoxy- (CA INDEX NAME)




RN 476475-96-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-ethoxy- (CA INDEX NAME)




RN 476475-97-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(phenylthio)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-98-6 CAPLUS

CN 2-Pyridinamine, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-N-phenyl- (CA INDEX NAME)




RN 476475-99-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(4-methoxyphenyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-00-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-phenyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-01-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(4-morpholinyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-02-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-pyrrolidinyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-03-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methoxy-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-04-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(phenylmethoxy)- (CA INDEX NAME)



RN 476476-05-8 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476476-06-9 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(3-fluoropropoxy)- (CA INDEX NAME)




RN 476476-07-0 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)




RN 476476-08-1 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-10-5 CAPLUS


CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)



RN 476476-11-6 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2R)-2-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-14-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-3-piperidinyl)methoxy]- (CA INDEX NAME)




RN 476476-15-0 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N,2-trimethyl- (CA INDEX NAME)




RN 476476-16-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-propoxy- (CA INDEX NAME)




RN 476476-17-2 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-
 [(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-18-3 CAPLUS
 CN Acetic acid, 2-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]-7-quinolinyl]oxy]-, methyl ester (CA INDEX NAME)



RN 476476-19-4 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]-7-(1-methylethoxy)- (CA INDEX NAME)




RN 476476-20-7 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 476476-23-0 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476476-24-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)



RN 476476-25-2 CAPLUS


CN Quinoline, 7-[(2,2-difluoro-1,3-benzodioxol-5-yl)methoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-26-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2S)-1-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-27-4 CAPLUS

CN 2-Pyrrolidinone, 5-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]methyl]- (CA INDEX NAME)




RN 476476-28-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-(phoxymethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-29-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-methylene-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-31-0 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
[(1-methyl-2-piperidinyl)methoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 476476-32-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)-4H-pyrrolo[1,2-
b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)



RN 476476-33-2 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
[2-(1-methyl-2-pyrrolidinyl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 476476-35-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
(methylsulfonyl)- (CA INDEX NAME)




RN 476476-38-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(methylsulfonyl)- (CA INDEX NAME)




RN 476476-39-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylsulfonyl)- (CA INDEX NAME)




RN 476476-40-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(2-pyrimidinylsulfonyl)propoxy]- (CA INDEX NAME)




RN 476476-41-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(1-methyl-1H-imidazol-2-yl)sulfonyl]propoxy]- (CA INDEX NAME)




RN 476476-42-3 CAPLUS

CN Quinoline, 7-[3-[(4-chlorophenyl)sulfonyl]propoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-43-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)sulfonyl]propoxy]- (CA INDEX NAME)



RN 476476-44-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)sulfinyl]propoxy]- (CA INDEX NAME)



RN 476476-46-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-,

1-oxide (CA INDEX NAME)




RN 476476-48-9 CAPLUS

CN 2-Propen-1-one, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 476476-49-0 CAPLUS

CN 2-Propenamide, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-50-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethenyl- (CA INDEX NAME)




RN 476476-51-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(phenylmethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-52-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(phenylmethyl)- (CA INDEX NAME)




RN 476476-53-6 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 476476-54-7 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-55-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476476-56-9 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclopentyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-57-0 CAPLUS

CN Benzoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-5-yl]- (CA INDEX NAME)




RN 476476-58-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476476-59-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)




RN 476476-60-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 476476-61-6 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(methylamino)propyl]- (CA INDEX NAME)




RN 476476-62-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-63-8 CAPLUS

CN Methanone, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-64-9 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclobutyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-65-0 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclopropyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-66-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 476476-67-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-ethyl- (CA INDEX NAME)




RN 476476-68-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 476476-69-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 476476-70-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 476476-71-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-propyl- (CA INDEX NAME)



RN 476476-72-9 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-methylbutyl)- (CA INDEX NAME)



RN 476476-73-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(2S)-2-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-74-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1S)-1-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-75-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1R)-1-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-76-3 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1R)-1,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-77-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-78-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-79-6 CAPLUS

CN Ethanone, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-81-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-82-1 CAPLUS

CN 2-Pyridinecarboxamide, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]- (CA INDEX NAME)




RN 476476-83-2 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-84-3 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)




RN 476476-86-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-89-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476476-91-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[4-(dimethylamino)butyl]- (CA INDEX NAME)




RN 476476-93-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-94-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476476-95-6 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-2-pyridinyl- (CA INDEX NAME)




RN 476476-96-7 CAPLUS

CN 7-Quinolinepropanamide, N-[2,2-bis(methylamino)ethyl]-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476476-97-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-98-9 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476476-99-0 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476477-00-6 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 476477-01-7 CAPLUS
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-02-8 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 476477-03-9 CAPLUS
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-04-0 CAPLUS
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-05-1 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476477-06-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-07-3 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrazide (CA INDEX NAME)




RN 476477-08-4 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-09-5 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(methylamino)propyl]- (CA INDEX NAME)




RN 476477-10-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-11-9 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrazide (CA INDEX NAME)




RN 476477-12-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-hydroxy- (CA INDEX NAME)




RN 476477-13-1 CAPLUS

CN 7-Quinolinecarboxamide, N-(2-aminoethyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-14-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-15-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-16-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476477-17-5 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-18-6 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476477-19-7 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-20-0 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476477-21-1 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-diethyl- (CA INDEX NAME)




RN 476477-24-4 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 476477-25-5 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-26-6 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 476477-27-7 CAPLUS

CN Propanamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 476477-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-29-9 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-31-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1-methylethyl]- (CA INDEX NAME)




RN 476477-32-4 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-33-5 CAPLUS

CN Methanesulfonamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476477-34-6 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1-methyl- (CA INDEX NAME)




RN 476477-35-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1-methylethyl]- (CA INDEX NAME)




RN 476477-36-8 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(3-(dimethylamino)propyl)- (CA INDEX NAME)




RN 476477-37-9 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-38-0 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 476477-40-4 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 476477-41-5 CAPLUS

CN Urea, N,N'-bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-42-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl ester (9CI) (CA INDEX NAME)




RN 476477-43-7 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 476477-44-8 CAPLUS

CN 6-Quinolinemethanol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 476477-45-9 CAPLUS

CN Quinoline, 7-[(3-chloropropyl)thio]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-47-1 CAPLUS

CN 7-Quinolinol, 8-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-48-2 CAPLUS

CN 7-Quinolinol, 8-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-50-6 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-4-methoxy-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-51-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazol-4-amine, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-53-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazol-4-one, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-54-0 CAPLUS

CN Benzonitrile, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-56-2 CAPLUS

CN Benzamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-58-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(6-methyl-3-pyridazinyl)oxy]- (CA INDEX NAME)




RN 476477-60-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butoxy]- (CA INDEX NAME)




RN 476477-65-3 CAPLUS

CN Benzenemethanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-66-4 CAPLUS

CN 2(1H)-Quinolinone, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476477-67-5 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 476477-68-6P, 6-Methoxy-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476477-70-0P, 4-[6-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-71-1P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]propionic acid methyl ester 476477-72-2P, 7-Amino-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-73-3P, N,N-Dimethyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-74-4P, N-[3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]acetamide 476477-75-5P, N-Acetyl-N-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-78-8P, Methyl [3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476477-80-2P, 7-(Piperidin-4-yloxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-84-6P, 7-(1-Methylpyrrolidin-3-

ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-85-7P, 7-(1-Methylpiperidin-4-ylmethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-86-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)amide 476477-94-8P, 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxazolidin-2-one 476477-95-9P, 1-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]imidazolidin-2-one 476477-96-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(pyridin-4-ylmethoxy)quinoline 476477-97-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-(pyridin-3-yl)propoxy)quinoline 476477-98-2P, 7-(4,5-Dihydro-1H-imidazol-2-yl)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476478-01-0P, 4-[2-(6-Vinylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476478-03-2P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]acrylic acid 476478-04-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-acetylminoethyl)amide 476478-05-4P, (R)-7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476478-06-5P 476478-07-6P 476478-08-7P 476478-09-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476477-68-6 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)




RN 476477-70-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-71-1 CAPLUS

CN 6-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476477-72-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-73-3 CAPLUS

CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-74-4 CAPLUS

CN Acetamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476477-75-5 CAPLUS

CN Acetamide, N-acetyl-N-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-78-8 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-methyl- (CA INDEX NAME)




RN 476477-80-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-piperidinylloxy)- (CA INDEX NAME)




RN 476477-84-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-3-pyrrolidinyl)methoxy]- (CA INDEX NAME)




RN 476477-85-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 476477-86-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1,1-dimethylethyl]- (CA INDEX NAME)




RN 476477-94-8 CAPLUS

CN 2-Oxazolidinone, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-95-9 CAPLUS

CN 2-Imidazolidinone, 1-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-96-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-pyridinylmethoxy)- (CA INDEX NAME)




RN 476477-97-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(3-pyridinyl)propoxy]- (CA INDEX NAME)




RN 476477-98-2 CAPLUS

CN Quinoline, 7-(4,5-dihydro-1H-imidazol-2-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-01-0 CAPLUS

CN Quinoline, 4-[2-(6-ethenyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-03-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinyl]- (CA INDEX NAME)



RN 476478-04-3 CAPLUS


CN 7-Quinolinecarboxamide, N-[2-(acetylamino)ethyl]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476478-05-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2R)-1-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476478-06-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-07-6 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476478-08-7 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-oxido-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 476478-09-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



IT 476476-80-9, [4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]acetic acid 476477-23-3,


7-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-79-9 476478-02-1,
4-[2-(6-Chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476476-80-9 CAPLUS

CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-23-3 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-79-9 CAPLUS

CN Carbamic acid, [3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 476478-02-1 CAPLUS

CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 476473-77-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(pyrimidin-2-ylsulfanyl)propoxy]quinoline 476473-81-1P 476473-82-2P, 7-[3-(4-Chlorophenylsulfanyl)propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-83-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(4-(pyrimidin-2-yl)piperazin-1-yl)propoxy]quinoline 476473-86-6P, 7-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-87-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(((pyridin-2-yl)methyl)sulfanyl)propoxy]quinoline 476473-91-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid 476474-00-7P, 4-[2-(6-Chloromethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-02-9P, Methanesulfonic acid [2-(pyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methyl ester 476474-10-9P, 4-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester 476474-12-1P, (Pyridin-2-yl) [3-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476474-13-2P, 7-(5-Chloropentyloxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-14-3P, 3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]methyl]pyrrolidine-1-carboxylic acid benzyl ester 476474-15-4P, Dimethyl [5-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]pentyl]amine 476474-16-5P, Methyl [5-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]pentyl]amine 476474-17-6P, 1,3-Bis[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]-1,3-dihydrobenzimidazol-2-one 476474-18-7P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-2-carboxylic acid ethyl ester 476474-24-5P, [2-Methyl-2-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carbonyl]amino]propyl]carbamic acid tert-butyl ester 476474-26-7P, 6-((tert-Butoxycarbonyl)amino)-2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carbonyl]amino]hexanoic acid methyl ester 476474-29-0P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-((tetrahydrofuran-2-yl)methoxy)quinoline 476474-30-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476473-77-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(2-pyrimidinylthio)propoxy]- (CA INDEX NAME)




RN 476473-81-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(1-methyl-1H-imidazol-2-yl)thio]propoxy]- (CA INDEX NAME)




RN 476473-82-2 CAPLUS

CN Quinoline, 7-[3-[(4-chlorophenyl)thio]propoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476473-83-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)




RN 476473-86-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(4-(2-methoxyphenyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)




RN 476473-87-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)thio]propoxy]- (CA INDEX NAME)




RN 476473-91-3 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-00-7 CAPLUS

CN Quinoline, 4-[2-[6-(chloromethyl)-2-pyridinyl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-02-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(2-pyridinyl)-3-(4-quinolinyl)-, 6-methanesulfonate (CA INDEX NAME)




RN 476474-10-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 476474-12-1 CAPLUS

CN 2-Pyridinamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476474-13-2 CAPLUS


CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476474-14-3 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)

pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy)methyl]-, phenylmethyl ester
(CA INDEX NAME)




RN 476474-15-4 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-16-5 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-methyl- (CA INDEX NAME)




RN 476474-17-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-bis[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1,3-dihydro- (CA INDEX NAME)




RN 476474-18-7 CAPLUS

CN 2-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)



RN 476474-24-5 CAPLUS


CN Carbamic acid, [2-[[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]carbonyl]amino]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 476474-26-7 CAPLUS


CN L-Lysine, N2-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]carbonyl]-N6-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)



RN 476474-30-3 CAPLUS

CN Quinoline, 7,7'-[1,5-pentanedibis(oxy)]bis[4-[5,6-dihydro-2-(2-
pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

79.46

460.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

| | ENTRY | SESSION |
|---------------------|-------|---------|
| CA SUBSCRIBER PRICE | -8.00 | -8.00 |

STN INTERNATIONAL LOGOFF AT 18:13:33 ON 17 JUN 2008